Novartis (NVS) CEO says capital allocation priorities remain unchanged, will continue to do value creating Bolt on deals, via JPM conference
Importance
Level 1
#JPMORGAN CHASE & CO#NOVARTIS AG#NVS.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#DIVERSIFIED BANKS#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#S&P 500 INDEX#JPM#US EQUITIES